Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (81388)	3/7/2001 9:11:43 AM
From: Jim Bishop	Read Replies (2) \| Respond to of 150070

NEOP Neoprobe Collaborators Receive Clearance to Begin Clinical Evaluation of Lymphatic Agent DUBLIN, Ohio--(BW HealthWire)--March 7, 2001--Neoprobe Corporation (OTCBB:NEOP - news) today announced that researchers at the University of California, San Diego (UCSD) Cancer Center have received clearance from the United States Food and Drug Administration to begin investigational clinical evaluation of a radiolabeled agent designed to assist in the more accurate surgical management and diagnosis of breast cancer patients. Patient enrollment in the randomized clinical study will begin shortly. Dr. Anne Wallace, assistant professor of surgery and director of the Breast Care Unit at UCSD Cancer Center, is the principal physician investigator evaluating the agent in breast cancer patients. Dr. Wallace's Phase I clinical study is being funded with a grant from the Susan G. Komen Breast Cancer Foundation. The clinical study will evaluate the agent's ability, when used with Neoprobe's hand-held gamma radiation detection instruments, to accurately identify tumor draining lymph nodes. Neoprobe has completed an option agreement with the Regents of the University of California to exclusively license the proprietary UCSD agent for diagnostic use. The agent, to which a radioactive isotope is attached, has shown considerable ability in preclinical studies to accurately identify lymphatic tissue. The accurate identification of the presence or absence of cancer in lymph nodes is of tremendous importance in determining the prognosis and management of breast cancer patients. Statements in this news release which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words ``believe,'' ``expect,'' ``anticipate,'' ``estimate,'' ``project,'' and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's limited revenues, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and exclusive distributor, uncertainty of market acceptance, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements. Contact: CONTACTS: Neoprobe Corporation David Bupp or Brent L. Larson, 614/793-7500 info@neoprobe.com www.neoprobe.com